Identifying treatment weaknesses in a specific type of myeloid leukemia.
Official title: Deciphering inv3/t(3;3) Myeloid Leukemia Vulnerabilities via Proteogenomics and N-terminal Proteomics
Funded at University of California Los Angeles · NIH-10997848 · Data updated 2026-11-12
This study is looking at a specific type of myeloid leukemia linked to changes in chromosome 3, and it aims to find new ways to treat patients who don’t have good options right now by comparing cancer cells to healthy blood cells to see what makes the disease more aggressive.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | August 1, 2024 |
| Project end | July 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $44,731 |
| NIH project number | 1F31CA295026-01 |
| Project ID | NIH-10997848 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with inv3/t(3;3) myeloid leukemia who have not responded to standard treatments.
✕Less likely to help
Patients with other types of leukemia or those who have not been diagnosed with inv3/t(3;3) abnormalities may not benefit from this research.
What this research studies
This research aims to uncover the unique vulnerabilities of myeloid leukemias associated with chromosome 3 rearrangements, specifically inv3/t(3;3). By utilizing advanced proteogenomic techniques, the study will compare cancerous cell lines with healthy blood cells to identify specific genes and proteins that contribute to the disease's aggressiveness. The goal is to find new therapeutic targets for patients who currently lack effective treatment options, as existing therapies have proven ineffective for this leukemia subtype.
Why it matters
Potential benefit: If successful, this research could lead to the development of targeted therapies that significantly improve survival rates for patients with inv3/t(3;3) myeloid leukemia.
How similar studies have gone: While research on myeloid leukemias is ongoing, this specific approach targeting inv3/t(3;3) vulnerabilities is relatively novel and has not been extensively tested.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Turmon, Alexandra Chloe — University of California Los Angeles
- Study coordinator: Turmon, Alexandra Chloe
Related research
Other NIH-funded projects on the same topics.
-
Investigating a specific type of leukemia in children caused by genetic changes.
This study is looking at how certain proteins linked to leukemia affect kids and teens with high-risk blood cancers, and the researchers hope to find new ways to treat these conditions by learning more about how the disease works.
-
Caregiver-led mobile tool to support healthy habits for kids treated for ALL
A caregiver-directed mobile program helps children who were treated for acute lymphoblastic leukemia build healthier daily routines.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Understanding TCRs in Leukemia to Improve Immunotherapies
A short, patient-friendly look at a project trying to map how immune cells recognize leukemia so future therapies can be better and safer for people with AML.
-
Targeted therapy for AML using DHODH inhibitors to boost differentiation and immune response
Aims to help adults with acute myeloid leukemia by using a special drug approach that makes cancer cells act more like normal blood cells and supports the immune system.
-
Genomics of childhood ALL across global populations
A wide-ranging study looks at how inherited genetics influence the risk of childhood acute lymphoblastic leukemia around the world.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.